Balachandra, Vinutha
Shrestha, Roshan L
Hammond, Colin M https://orcid.org/0000-0003-0571-5710
Lin, Shinjen
Hendriks, Ivo A https://orcid.org/0000-0002-1439-3701
Sethi, Subhash Chandra
Chen, Lu
Sevilla, Samantha https://orcid.org/0000-0002-8734-9875
Caplen, Natasha J
Chari, Raj https://orcid.org/0000-0002-2216-313X
Karpova, Tatiana S https://orcid.org/0000-0001-6025-2128
McKinnon, Katherine
Todd, Matthew AM https://orcid.org/0000-0002-1587-3571
Koparde, Vishal https://orcid.org/0000-0001-8978-8495
Cheng, Ken Chih-Chien
Nielsen, Michael L
Groth, Anja
Basrai, Munira A https://orcid.org/0000-0003-0628-8052
Funding for this research was provided by:
HHS | NIH | NCI | Center for Cancer Research (ZIA BC 010822)
HHS | NIH | NCI | Center for Cancer Research (ZIA BC 011704)
HHS | NIH | NCI | Center for Cancer Research (75N91019D00024)
HHS | NIH | National Cancer Institute (HHSN261201500003I)
Independent Research Fund Denmark, European Union’s Horizon 2020 research and innovation program, Danish Cancer Society (0135-00096B and 8020-00220B,EPIC-XS-823839,R146-A9159-16-S2)
European Research Council, Lund-beck Foundation, Independent Research Fund Denmark, Novo Nordisk Foundation (ERC CoG 724436,R198-2015-269 and R313-2019-448,7016-00042B,NNF21OC0067425,NNF14CC0001)
NIH Intramural Research Program, Intramural Research Program of the National Center for Advancing Translational Sciences
Article History
Received: 28 September 2023
Revised: 20 March 2024
Accepted: 25 March 2024
First Online: 10 April 2024
Disclosure and competing interests statement
: CMH and AG are inventors on a filed patent application covering the therapeutic targeting of TONSL for cancer therapy. AG is a co-founder and chief scientific officer (CSO) of Ankrin Therapeutics. The remaining authors declare no competing interests.